Catalent Inc (NASDAQ:CTLT) – Investment analysts at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of Catalent in a note issued to investors on Thursday. Jefferies Group analyst D. Windley now expects that the firm will post earnings of $1.33 per share for the year, up from their previous forecast of $1.31. Jefferies Group has a “Hold” rating and a $28.00 price target on the stock.
CTLT has been the topic of a number of other reports. Piper Jaffray Cos. restated an “overweight” rating and set a $30.00 price objective (down from $30.50) on shares of Catalent in a report on Tuesday, August 30th. Morgan Stanley restated a “hold” rating on shares of Catalent in a report on Tuesday, August 30th. Zacks Investment Research upgraded shares of Catalent from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 5th. TheStreet upgraded shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 17th. Finally, Wells Fargo & Co. upgraded shares of Catalent from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $28.67.
Catalent (NASDAQ:CTLT) opened at 25.84 on Monday. The firm has a market cap of $3.22 billion and a price-to-earnings ratio of 29.03. Catalent has a 52-week low of $18.92 and a 52-week high of $32.24. The firm’s 50-day moving average is $25.22 and its 200-day moving average is $25.66.
Catalent (NASDAQ:CTLT) last released its earnings results on Monday, August 29th. The company reported $0.52 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.53 by $0.01. The business had revenue of $532.20 million for the quarter. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.61 earnings per share.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DIAM Co. Ltd. increased its position in Catalent by 10.4% in the second quarter. DIAM Co. Ltd. now owns 99,921 shares of the company’s stock worth $2,270,000 after buying an additional 9,418 shares during the period. California State Teachers Retirement System increased its position in shares of Catalent by 17.8% in the second quarter. California State Teachers Retirement System now owns 209,227 shares of the company’s stock worth $4,810,000 after buying an additional 31,570 shares during the period. Bank of New York Mellon Corp increased its position in shares of Catalent by 6.5% in the second quarter. Bank of New York Mellon Corp now owns 1,202,407 shares of the company’s stock worth $27,644,000 after buying an additional 73,250 shares during the period. Oxford Asset Management increased its position in shares of Catalent by 245.6% in the second quarter. Oxford Asset Management now owns 34,291 shares of the company’s stock worth $788,000 after buying an additional 24,369 shares during the period. Finally, Alps Advisors Inc. increased its position in shares of Catalent by 25.1% in the second quarter. Alps Advisors Inc. now owns 175,122 shares of the company’s stock worth $4,026,000 after buying an additional 35,081 shares during the period.
In related news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the firm’s stock in a transaction on Friday, September 9th. The shares were sold at an average price of $23.58, for a total value of $403,234,623.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.